[go: up one dir, main page]

IN2012DN01209A - - Google Patents

Info

Publication number
IN2012DN01209A
IN2012DN01209A IN1209DEN2012A IN2012DN01209A IN 2012DN01209 A IN2012DN01209 A IN 2012DN01209A IN 1209DEN2012 A IN1209DEN2012 A IN 1209DEN2012A IN 2012DN01209 A IN2012DN01209 A IN 2012DN01209A
Authority
IN
India
Prior art keywords
composition
disclosed
treating
disorders
compound
Prior art date
Application number
Other languages
English (en)
Inventor
V Staubli Ursula
E Donello John
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of IN2012DN01209A publication Critical patent/IN2012DN01209A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
IN1209DEN2012 2009-07-17 2010-07-16 IN2012DN01209A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22642509P 2009-07-17 2009-07-17
PCT/US2010/042308 WO2011009061A1 (fr) 2009-07-17 2010-07-16 Compositions comprenant un inhibiteur de la cholinestérase pour traiter des troubles cognitifs

Publications (1)

Publication Number Publication Date
IN2012DN01209A true IN2012DN01209A (fr) 2015-04-10

Family

ID=42990151

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1209DEN2012 IN2012DN01209A (fr) 2009-07-17 2010-07-16

Country Status (14)

Country Link
US (2) US20110015179A1 (fr)
EP (1) EP2453890B1 (fr)
JP (1) JP2012533566A (fr)
KR (1) KR101757003B1 (fr)
CN (1) CN102497861A (fr)
AU (1) AU2010273977A1 (fr)
BR (1) BR112012001047A2 (fr)
CA (1) CA2768356A1 (fr)
DK (1) DK2453890T3 (fr)
ES (1) ES2809298T3 (fr)
IN (1) IN2012DN01209A (fr)
PT (1) PT2453890T (fr)
RU (2) RU2016151986A (fr)
WO (1) WO2011009061A1 (fr)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5A (en) * 1836-08-10 Thomas Blanchard Machine for mortising solid wooden shells of ships' tackle-blocks
US4166452A (en) * 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US5409948A (en) * 1992-11-23 1995-04-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method for treating cognitive disorders with phenserine
US20050222123A1 (en) 2004-01-27 2005-10-06 North Shore-Long Island Jewish Research Institute Cholinesterase inhibitors for treating inflammation
US20070212253A1 (en) * 2004-12-21 2007-09-13 Elrod Scott A Descenting systems and methods
NZ556614A (en) * 2005-01-26 2010-10-29 Allergan Inc 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroayryl-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic and/or immunostimulant activity
CA2616858A1 (fr) * 2005-07-27 2007-02-01 Carlos Henrique Horta Lima Preparation pharmaceutique contenant un inhibiteur de l'acetylcholinesterase et un antidepresseur ayant des proprietes bloquant la 5-ht et l'alpha-2-adrenocepteur.
AU2006282896A1 (en) * 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
WO2008109285A1 (fr) * 2007-03-06 2008-09-12 Allergan, Inc. Procédés de traitement de troubles cognitifs
US20100105687A1 (en) * 2007-03-06 2010-04-29 Allergan, Inc. Methods for treating cognitive disorders using 1-aryl-1-hydroxy-2,3-diamino-propyl amines, 1-heteroaryl-1-hydroxy-2,3-diamino-propyl amines and related compounds
US20100190792A1 (en) * 2007-03-06 2010-07-29 Allergan, Inc Methods for treating cognitive disorders using 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds
EP2481407B1 (fr) * 2007-03-06 2018-09-26 Allergan, Inc. Composés à utiliser dans le traitement des troubles cognitifs
JP2010533720A (ja) * 2007-07-17 2010-10-28 アラーガン、インコーポレイテッド 不安を処置するための方法

Also Published As

Publication number Publication date
CN102497861A (zh) 2012-06-13
DK2453890T3 (da) 2020-08-17
EP2453890A1 (fr) 2012-05-23
JP2012533566A (ja) 2012-12-27
EP2453890B1 (fr) 2020-05-27
KR20120090029A (ko) 2012-08-16
US9492543B2 (en) 2016-11-15
BR112012001047A2 (pt) 2019-09-24
PT2453890T (pt) 2020-08-25
RU2012103401A (ru) 2013-08-27
RU2016151986A (ru) 2018-12-19
ES2809298T3 (es) 2021-03-03
RU2607946C2 (ru) 2017-01-11
WO2011009061A1 (fr) 2011-01-20
US20130040938A1 (en) 2013-02-14
CA2768356A1 (fr) 2011-01-20
AU2010273977A1 (en) 2012-02-02
US20110015179A1 (en) 2011-01-20
KR101757003B1 (ko) 2017-07-11

Similar Documents

Publication Publication Date Title
PH12013500975A1 (en) Nampt and rock inhibitors
IN2012DN03883A (fr)
JO2892B1 (en) CYP inhibitors 17
MY199894A (en) Prmt5 inhibitors and uses thereof
EA201200373A1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназ
MX2012004780A (es) Inhibidores de akt.
MY152271A (en) Novel compounds that are erk inhibitors
MX2011009796A (es) Inhibidores de la cinasa pi3.
MX2011011854A (es) Dihidropirimidinonas para uso como inhibidores de la bace2.
WO2011014795A3 (fr) Composés et compositions pouvant servir d'inhibiteurs de la kinase syk
UA104885C2 (uk) Ізотіазолілоксифеніламідини та їх застосування як фунгіцидів
MX2010002732A (es) Inhibidores de f1f0-atpasa y metodos relacionados.
MX2013007336A (es) Compuestos de bi-heteroarilo como inhibidores de vps34.
GEP20125708B (en) Hydroxamate-based inhibitors of deacetylases b
UA103930C2 (ru) Соединения и композиция для лечения паразитарных болезней
MX2013002851A (es) Inhibidores de tonum pectinacetilesterasa y metodos de su uso.
IN2012DN03182A (fr)
IN2012DN01273A (fr)
AU2011326186A8 (en) Selective glycosidase inhibitors and uses thereof
MX2009005649A (es) Tratamiento para mieloma multiple.
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
PH12016502534A1 (en) Azaquinazoline carboxamide derivatives
IN2012DN03846A (fr)
WO2011088160A3 (fr) Nouveaux inhibiteurs de cyp17
MX338441B (es) Uso de 2,3-dihidroxipropil dodecanoato para tratar seborrea.